TY - JOUR
T1 - Sarcopenia is associated with poor prognosis after chemoradiotherapy in patients with stage III non-small-cell lung cancer
T2 - a retrospective analysis
AU - Katsui, Kuniaki
AU - Ogata, Takeshi
AU - Sugiyama, Soichi
AU - Yoshio, Kotaro
AU - Kuroda, Masahiro
AU - Hiraki, Takao
AU - Kiura, Katsuyuki
AU - Maeda, Yoshinobu
AU - Toyooka, Shinichi
AU - Kanazawa, Susumu
N1 - Funding Information:
We thank all participants whose data was used in this study. We are grateful to Dr. Keiji Matsuda and Dr. Kimiko Nishigaki (Department of Radiology, Okayama University Hospital), Dr. Toshio Kubo (Center for Clinical Oncology, Okayama University Hospital), and Dr. Nobuaki Ochi (Department of General Internal Medicine 4, Kawasaki Hospital, Kawasaki Medical School) for their assistance with the data collection. This research was funded by Tsuyama Chuo Hospital. The sponsors of this study were not involved in the conduct of this study, including the study design, data collection, data analysis, data interpretation, manuscript writing, or the decision to submit the manuscript for publication. We would like to thank Editage (www.editage.com) for English language editing.
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - We intended to investigate whether muscle and adipose masses were associated with prognosis among patients with stage III non-small-cell lung cancer (NSCLC) who were undergoing chemoradiotherapy (CCRT). We retrospectively explored data of patients with stage III NSCLC who underwent definitive CCRT (≥ 60 Gy) between January 2004 and March 2018 at our hospital. We examined the relationship of overall survival (OS) with body mass index (BMI), skeletal muscle index (SMI), psoas muscle index (PMI), visceral adipose tissue index (VAI), subcutaneous adipose tissue index (SAI), and visceral-to-subcutaneous adipose tissue area ratio (VSR) using log-rank tests for the univariate analysis and Cox proportional hazard models for the multivariate analysis. Overall, 16, 32, and 12 patients had stage IIIA, IIIB, and IIIC NSCLC, respectively. The total radiotherapy dose ranged from 60 Gy/30 fractions to 66 Gy/33 fractions. In the univariate analysis, the performance status (PS), BMI, and SMI were associated with OS, whereas the PMI, VAI, SAI, and VSR were not. In the multivariate analysis, the PS and SMI were associated with OS. The hazard ratios and 95% confidence intervals were 2.91 and 1.28–6.64 for PS, and 2.36 and 1.15–4.85 for SMI, respectively. The 1, 3, and 5-year OS rates were 92.1%, 59.6%, and 51.0% in patients with high SMI, and 63.6%, 53.8%, and 17.9% in patients with low SMI, respectively. The SMI correlated with prognosis in our study population, whereas adipose mass did not. Therefore, sarcopenia should be considered while predicting the OS in such patients.
AB - We intended to investigate whether muscle and adipose masses were associated with prognosis among patients with stage III non-small-cell lung cancer (NSCLC) who were undergoing chemoradiotherapy (CCRT). We retrospectively explored data of patients with stage III NSCLC who underwent definitive CCRT (≥ 60 Gy) between January 2004 and March 2018 at our hospital. We examined the relationship of overall survival (OS) with body mass index (BMI), skeletal muscle index (SMI), psoas muscle index (PMI), visceral adipose tissue index (VAI), subcutaneous adipose tissue index (SAI), and visceral-to-subcutaneous adipose tissue area ratio (VSR) using log-rank tests for the univariate analysis and Cox proportional hazard models for the multivariate analysis. Overall, 16, 32, and 12 patients had stage IIIA, IIIB, and IIIC NSCLC, respectively. The total radiotherapy dose ranged from 60 Gy/30 fractions to 66 Gy/33 fractions. In the univariate analysis, the performance status (PS), BMI, and SMI were associated with OS, whereas the PMI, VAI, SAI, and VSR were not. In the multivariate analysis, the PS and SMI were associated with OS. The hazard ratios and 95% confidence intervals were 2.91 and 1.28–6.64 for PS, and 2.36 and 1.15–4.85 for SMI, respectively. The 1, 3, and 5-year OS rates were 92.1%, 59.6%, and 51.0% in patients with high SMI, and 63.6%, 53.8%, and 17.9% in patients with low SMI, respectively. The SMI correlated with prognosis in our study population, whereas adipose mass did not. Therefore, sarcopenia should be considered while predicting the OS in such patients.
UR - http://www.scopus.com/inward/record.url?scp=85107111083&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107111083&partnerID=8YFLogxK
U2 - 10.1038/s41598-021-91449-z
DO - 10.1038/s41598-021-91449-z
M3 - Article
C2 - 34088965
AN - SCOPUS:85107111083
SN - 2045-2322
VL - 11
JO - Scientific reports
JF - Scientific reports
IS - 1
M1 - 11882
ER -
